SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-17-004538
Filing Date
2017-03-15
Accepted
2017-03-15 09:09:39
Documents
16
Period of Report
2017-03-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20170314_8k.htm 8-K 55486
2 EXHIBIT 3.1 ex3-1.htm EX-3.1 6818
3 EXHIBIT 4.1 ex4-1.htm EX-4.1 79086
4 EXHIBIT 10.1 ex10-1.htm EX-10.1 175012
5 EXHIBIT 10.2 ex10-2.htm EX-10.2 160249
6 a11.jpg GRAPHIC 127847
7 a10.jpg GRAPHIC 57169
8 a9.jpg GRAPHIC 283497
9 a8.jpg GRAPHIC 382297
10 a7.jpg GRAPHIC 407336
11 a6.jpg GRAPHIC 418968
12 a5.jpg GRAPHIC 361032
13 a4.jpg GRAPHIC 368442
14 a3.jpg GRAPHIC 388352
15 a2.jpg GRAPHIC 309453
16 a1.jpg GRAPHIC 106593
  Complete submission text file 0001437749-17-004538.txt   4900655
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 17689981
SIC: 2834 Pharmaceutical Preparations